Schering AG
 |
|
| Industry | Pharmaceutical |
|---|---|
| Fate | Merged |
| Successor |
Bayer Schering Pharma AG Bayer HealthCare Pharmaceuticals |
| Founded | 1851 |
| Defunct | 2006 |
| Headquarters | Berlin-Wedding, Germany |
|
Key people
|
Hubertus Erlen, last CEO |
| Products |
Gynaecology & Andrology Special therapeutics Diagnostical devices & Nuclear medicine Oncology |
|
Number of employees
|
26,000 (2004) |
| Website | www |
Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the and had 26,000 employees as of 2004.
The American pharmaceutical company Schering-Plough, formerly the Schering Corporation, was originally the US subsidiary of Schering AG, and merged with Merck & Co. in 2009.
It was founded in 1851 by Ernst Christian Friedrich Schering (1824–1889) and merged with Bayer's pharmaceutical division in December 2006. The company's headquarters was in Berlin-Wedding, Germany (part of West Berlin during the Cold War). In North America, Schering operated mainly under the Berlex Laboratories brand.
At the time of the merger, the company employed more than 26,000 people in 140 subsidiaries worldwide. Schering's annual gross revenue was nearly €5 billion (2003).
Schering AG focused on the business areas of gynaecology, andrology, multiple sclerosis, oncology, and contrast agents. Schering best-known products are probably its brands of combined oral contraceptive pills. Other key products included the interferon-beta brand Betaferon (Betaseron in North America) and the paramagnetic contrast agent Magnevist.
...
Wikipedia